Skye Bioscience (SKYE) Competitors $0.73 -0.05 (-6.75%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$0.74 +0.01 (+1.90%) As of 05/19/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SKYE vs. THAR, VTVT, AIFC, PEPG, and TTRXShould you buy Skye Bioscience stock or one of its competitors? MarketBeat compares Skye Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Skye Bioscience include Tharimmune (THAR), vTv Therapeutics (VTVT), ALT5 Sigma (AIFC), PepGen (PEPG), and Turn Therapeutics (TTRX). These companies are all part of the "pharmaceutical products" industry. SKYE vs. THARSKYE vs. VTVTSKYE vs. AIFCSKYE vs. PEPGSKYE vs. TTRXHow does Skye Bioscience compare to Tharimmune?Tharimmune (NASDAQ:THAR) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations. Is THAR or SKYE more profitable? Skye Bioscience's return on equity of -217.27% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets TharimmuneN/A -588.45% -264.41% Skye Bioscience N/A -217.27%-162.39% Which has more risk and volatility, THAR or SKYE? Tharimmune has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 3.03, suggesting that its stock price is 203% more volatile than the broader market. Do insiders & institutionals believe in THAR or SKYE? 1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 6.7% of Tharimmune shares are owned by company insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer THAR or SKYE? In the previous week, Skye Bioscience had 1 more articles in the media than Tharimmune. MarketBeat recorded 3 mentions for Skye Bioscience and 2 mentions for Tharimmune. Skye Bioscience's average media sentiment score of 0.26 beat Tharimmune's score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tharimmune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend THAR or SKYE? Skye Bioscience has a consensus target price of $9.80, indicating a potential upside of 1,251.35%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than Tharimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.63 Which has higher earnings and valuation, THAR or SKYE? Tharimmune is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTharimmuneN/AN/A-$12.20M-$3.99N/ASkye BioscienceN/AN/A-$55.92M-$1.44N/A SummarySkye Bioscience beats Tharimmune on 12 of the 14 factors compared between the two stocks.How does Skye Bioscience compare to vTv Therapeutics?vTv Therapeutics (NASDAQ:VTVT) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation. Which has stronger earnings and valuation, VTVT or SKYE? vTv Therapeutics has higher revenue and earnings than Skye Bioscience. vTv Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiovTv Therapeutics$1.02M140.95-$26.97M-$0.93N/ASkye BioscienceN/AN/A-$55.92M-$1.44N/A Does the media favor VTVT or SKYE? In the previous week, vTv Therapeutics had 13 more articles in the media than Skye Bioscience. MarketBeat recorded 16 mentions for vTv Therapeutics and 3 mentions for Skye Bioscience. vTv Therapeutics' average media sentiment score of 0.53 beat Skye Bioscience's score of 0.26 indicating that vTv Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, VTVT or SKYE? vTv Therapeutics has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Skye Bioscience has a beta of 3.03, indicating that its stock price is 203% more volatile than the broader market. Is VTVT or SKYE more profitable? vTv Therapeutics' return on equity of 3.96% beat Skye Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets vTv TherapeuticsN/A 3.96% 2.86% Skye Bioscience N/A -217.27%-162.39% Do institutionals and insiders believe in VTVT or SKYE? 17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Comparatively, 6.2% of Skye Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate VTVT or SKYE? vTv Therapeutics currently has a consensus price target of $53.00, indicating a potential upside of 45.25%. Skye Bioscience has a consensus price target of $9.80, indicating a potential upside of 1,251.35%. Given Skye Bioscience's higher possible upside, analysts clearly believe Skye Bioscience is more favorable than vTv Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.63 SummaryvTv Therapeutics beats Skye Bioscience on 9 of the 14 factors compared between the two stocks.How does Skye Bioscience compare to ALT5 Sigma?ALT5 Sigma (NASDAQ:AIFC) and Skye Bioscience (NASDAQ:SKYE) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations. Does the media prefer AIFC or SKYE? In the previous week, Skye Bioscience had 1 more articles in the media than ALT5 Sigma. MarketBeat recorded 3 mentions for Skye Bioscience and 2 mentions for ALT5 Sigma. Skye Bioscience's average media sentiment score of 0.26 beat ALT5 Sigma's score of -0.07 indicating that Skye Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate AIFC or SKYE? Skye Bioscience has a consensus target price of $9.80, indicating a potential upside of 1,251.35%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Skye Bioscience is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.63 Is AIFC or SKYE more profitable? Skye Bioscience has a net margin of 0.00% compared to ALT5 Sigma's net margin of -1,386.90%. ALT5 Sigma's return on equity of -50.52% beat Skye Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets ALT5 Sigma-1,386.90% -50.52% -45.05% Skye Bioscience N/A -217.27%-162.39% Which has more risk and volatility, AIFC or SKYE? ALT5 Sigma has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 3.03, suggesting that its stock price is 203% more volatile than the broader market. Do insiders and institutionals have more ownership in AIFC or SKYE? 6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable valuation and earnings, AIFC or SKYE? Skye Bioscience has lower revenue, but higher earnings than ALT5 Sigma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALT5 Sigma$24.84M4.40-$344.51MN/AN/ASkye BioscienceN/AN/A-$55.92M-$1.44N/A SummarySkye Bioscience beats ALT5 Sigma on 11 of the 14 factors compared between the two stocks.How does Skye Bioscience compare to PepGen?PepGen (NASDAQ:PEPG) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment. Is PEPG or SKYE more profitable? PepGen's return on equity of -59.89% beat Skye Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets PepGenN/A -59.89% -49.62% Skye Bioscience N/A -217.27%-162.39% Do analysts rate PEPG or SKYE? PepGen presently has a consensus price target of $11.60, suggesting a potential upside of 740.58%. Skye Bioscience has a consensus price target of $9.80, suggesting a potential upside of 1,251.35%. Given Skye Bioscience's higher probable upside, analysts plainly believe Skye Bioscience is more favorable than PepGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.63 Which has more risk & volatility, PEPG or SKYE? PepGen has a beta of 2.01, meaning that its stock price is 101% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 3.03, meaning that its stock price is 203% more volatile than the broader market. Does the media prefer PEPG or SKYE? In the previous week, PepGen had 7 more articles in the media than Skye Bioscience. MarketBeat recorded 10 mentions for PepGen and 3 mentions for Skye Bioscience. PepGen's average media sentiment score of 1.12 beat Skye Bioscience's score of 0.26 indicating that PepGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, PEPG or SKYE? PepGen is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPepGenN/AN/A-$89.65M-$1.75N/ASkye BioscienceN/AN/A-$55.92M-$1.44N/A Do insiders & institutionals have more ownership in PEPG or SKYE? 58.0% of PepGen shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 1.3% of PepGen shares are owned by insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryPepGen and Skye Bioscience tied by winning 7 of the 14 factors compared between the two stocks.How does Skye Bioscience compare to Turn Therapeutics?Skye Bioscience (NASDAQ:SKYE) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Which has preferable earnings and valuation, SKYE or TTRX? Turn Therapeutics is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkye BioscienceN/AN/A-$55.92M-$1.44N/ATurn TherapeuticsN/AN/A-$3.19M-$0.19N/A Do institutionals and insiders hold more shares of SKYE or TTRX? 21.1% of Skye Bioscience shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate SKYE or TTRX? Skye Bioscience presently has a consensus target price of $9.80, suggesting a potential upside of 1,251.35%. Turn Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 75.82%. Given Skye Bioscience's stronger consensus rating and higher possible upside, equities research analysts plainly believe Skye Bioscience is more favorable than Turn Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.63Turn Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer SKYE or TTRX? In the previous week, Turn Therapeutics had 3 more articles in the media than Skye Bioscience. MarketBeat recorded 6 mentions for Turn Therapeutics and 3 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 0.26 beat Turn Therapeutics' score of 0.13 indicating that Skye Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is SKYE or TTRX more profitable? Turn Therapeutics' return on equity of 0.00% beat Skye Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Skye BioscienceN/A -217.27% -162.39% Turn Therapeutics N/A N/A N/A SummarySkye Bioscience beats Turn Therapeutics on 8 of the 13 factors compared between the two stocks. Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SKYE vs. The Competition ExportMetricSkye BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.33M$3.25B$6.24B$12.23BDividend YieldN/A2.34%2.80%5.32%P/E Ratio-0.5018.5220.7925.05Price / SalesN/A270.32531.2172.68Price / CashN/A124.5843.0954.25Price / Book2.796.609.816.83Net Income-$55.92M$24.18M$3.55B$335.69M7 Day Performance-11.53%-3.74%-2.11%-2.15%1 Month Performance-7.43%-7.95%-4.14%-2.47%1 Year Performance-63.19%50.32%28.35%27.13% Skye Bioscience Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SKYESkye Bioscience2.2781 of 5 stars$0.73-6.8%$9.80+1,251.4%-66.3%$27.33MN/AN/A11Gap DownTHARTharimmune0.0068 of 5 stars$3.19+5.6%N/A+127.4%$120.36MN/AN/A2News CoverageVTVTvTv Therapeutics3.0315 of 5 stars$32.11+5.4%$53.00+65.1%+71.7%$119.98M$1.02MN/A9Earnings ReportAnalyst UpgradeAnalyst RevisionAIFCALT5 Sigma0.1728 of 5 stars$0.90-3.5%N/A-87.4%$118.66M$24.84MN/A170Earnings ReportPEPGPepGen3.8506 of 5 stars$1.68-1.2%$11.80+602.4%-7.4%$117.59MN/AN/A30Positive News Related Companies and Tools Related Companies THAR Alternatives VTVT Alternatives AIFC Alternatives PEPG Alternatives TTRX Alternatives BMEA Alternatives CRDF Alternatives KLRS Alternatives CYPH Alternatives ALDX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SKYE) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredHe doesn't buy gold. He just profits from it.Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...Brownstone Research | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
